EIElena Yu. Ilyina

Elena Yu. Ilyina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena Yu. Ilyina has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-term toxicities of chemoradiotherapy in children with standard-risk medulloblastoma

    by A. N. Flegontov, A. E. Druy, A. V. Protsvetkina, D. R. Gaynullina, M. A. Evdokimova, E. Yu. Ilyina, A. V. Artyomov, V. V. Gornostaev, Е. А. Сальникова, A. E. Sysoev, et al.

    Background. Medulloblastoma (MB) is one of the most common malignant brain tumors in children. In the standard-risk group, 5-year overall survival reaches 75–85 %, however, high treatment efficacy is accompanied by a considerable risk of late toxic effects that substantially impact patients’ quality of life. The most prevalent complications include cognitive and endocrine disorders, sensorineural hearing loss, and scoliosis. Long-term follow-up of survivors remains non-standardized. The aim of this study was to comprehensively assess the spectrum and frequency of late effects after chemoradiotherapy in children with standard-risk MB and to identify factors influencing their development. Materials and methods . A retrospective analysis was performed in 144 patients with standard-risk MB treated at the Dmitry Rogachev National Medical Research Center between 2013 and 2023. All patients received craniospinal irradiation at a dose of 23.4–24.0 Gy or 35.2–36.0 Gy with a posterior fossa boost to 54–55 Gy, followed by maintenance chemotherapy (lomustine, cisplatin, vincristine). To assess late effects (endocrine dysfunction, sensorineural hearing loss, scoliosis, chronic nutritional deficiency, polyneuropathy), detailed clinical and laboratory data were available for 55 patients, neurocognitive outcomes were analyzed in 30, and oncologic follow-up for secondary tumors in all 144. The cumulative incidence of complications was estimated using competing-risks methodology, subgroup comparisons were performed with Gray’s test, with p < 0.05 considered statistically significant. Results. The median age at the start of radiotherapy was 8.2 years, median follow-up 3.2 years. The most frequent late effects were cognitive (96.7 %) and endocrine disorders (89.1 %). Less frequent complications included scoliosis (50.9 %), sensorineural hearing loss (47.3 %), nutritional deficiency (32.7 %), and polyneuropathy (25.5 %), secondary neoplasms occurred in 4.2 % of patients. The most common cognitive impairments involved reduced psychomotor speed, attention, memory, emotional stability, and learning ability. Following therapy, a statistically significant increase was observed in the frequency of memory impairment (p = 0.01) and learning difficulties (p = 0.027). Growth hormone deficiency was detected in 70.1 % of patients (median time to onset – 1.7 years), the diagnosis was confirmed in 43 %, and growth hormones replacement therapy was initiated in only one-third. Hypothyroidism was diagnosed in 69.1 %, secondary adrenal insufficiency in 21.8 %, and gonadal dysfunction in 16.4 %. Growth hormone deficiency and hypothyroidism developed significantly earlier in patients who received craniospinal irradiation 35.2 Gy, although their long-term cumulative incidence was similar to those treated with 23.4 Gy. The 6-year cumulative incidence of secondary neoplasms was 4.7 %; most were high-grade diffuse gliomas (n = 3) with a median survival not exceeding one year. Conclusion s. Chemoradiotherapy for standard-risk MB is associated with a wide spectrum of late toxicities, predominantly cognitive and endocrine, most of which can be effectively managed when detected in a timely manner. Unwarranted de-escalation of therapy without reliable prognostic justification is unacceptable due to the high risk of fatal relapse. Systematic long-term monitoring of late effects, application of modern toxicity-reduction approaches, and comprehensive rehabilitation programs are essential components of optimal survivorship care for patients with MB.

  • Open Access

    Gonadal function in male pediatric patients after allogeneic hematopoietic stem cell transplantation: a comparison of the effects of treosulfan- and total body irradiation-based conditioning

    by Elvira R. Sultanova, Elena Yu. Ilyina, Daria A. Shasheleva, Alexey A. Vinokurov, Anastasia V. Protsvetkina, Wassili M. Delyagin, Yulia V. Skvortsova, Делягин Василий Михайлович, Скворцова Юлия Валериевна

    Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for many orphan diseases that can significantly improve prognosis and survival in patients. Conditioning prior to HSCT includes alkylating agents and/or total body irradiation (TBI) that are both known to be highly gonadotoxic. This is why it is so important to choose drugs and treatment options with minimal side effects. The aim of our study was to evaluate the reproductive function of male HSCT recipients who had received treosulfan- and TBI-based conditioning. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. We included 112 boys. The concentrations of follicle-stimulating and luteinizing hormones, testosterone levels, testicular size (measured using ultrasound) and pubertal development (as per the Tanner scale) were assessed over time. The obtained data showed that the effect of treosulfan on gonadal function in the males was less significant than that of TBI, with the cumulative probability of developing hypogonadism at 4 years after HSCT equaling 0% and 24% respectively. However, the toxicity of other alkylating agents included in a treosulfan-based conditioning regimen eliminates the difference in the cumulative probability of hypogonadism between the two approaches. Further annual monitoring is needed to fully understand the reproductive potential of the patients.

  • Open Access

    Long-term musculoskeletal side effects in patients with neuroblastoma who have completed specific therapy (case reports and literature review)

    by D. T. Utalieva, D. Yu. Kachanov, E. Yu. Ilyina, A. V. Popa, A. V. Nechesnyuk, T. V. Shamanskaya, Е. Ю. Ильина

    Neuroblastoma (NB) is the most common extracranial solid tumor in children. The stratification of patients into risk groups has led to the development of therapeutic protocols with intensification of therapy in high-risk patients and minimal treatment, up to the complete abandonment of chemotherapy in patients with a potentially favorable long-term prognosis. The implementation of multimodal therapy in the intermediate/high-risk group patients significantly improved long-term survival rates. However, anticancer treatment inevitably leads to a wide range of undesirable effects and long-term consequences, including negative effects on the musculoskeletal tissue and teeth. The main factors leading to the pathology of the musculoskeletal system include chemotherapy, including high-dose chemotherapy with autologous hematopoietic stem cell transplantation, radiation therapy and other methods of treatment. In addition, the localization of a primary tumor and metastases creates a potential threat of the development of undesirable effects on the musculoskeletal system, including for patients from the observation group. The article presents a description of clinical cases of musculoskeletal toxicity in patients with NB who completed specific treatment with a literature review on this topic. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.

  • PRIMARY HYPERPARATHYROIDISM CAUSED BY THE PARATHYROID ADENOMA ECTOPIC IN THE THYMUS: A CLINICAL CASE

    by N.G. Uskova, Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology, N.V. Babaskina, E.Yu. Il’ina, D.S. Abramov, M.A. Kurnikova, D.G. Akhaladze, N.S. Grachev

    Primary hyperparathyroidism (or PHPT) is a rare pediatric disease occurring in 1 case per 200 to 300 thousand children. The most common cause of PHPT in the adult population is a solitary parathyroid (PT) adenoma with up to 16% of PT adenomas having an ectopic location. There are no epidemiological data on pancreatic adenomas in pediatric population including atypically located ones, and clinical data are extremely scarce. This article describes a clinical observation of an adolescent patient with PHPT whose disease has been manifested with increased fragility and deformation of the bones of the skeleton. Only one year after the onset of primary symptoms a complex set of diagnostic measures was initiated, as a result of which a diagnosis was established: PHPT against the background of adenoma of the pancreas, ectopic in the left lobe of the thymus. The surgical treatment was carried out in the amount of thoracoscopic hemithymectomy which led to the relief of hyperparathyroidism. Despite the surgical intervention the systemic osteoporosis and persistent pathological changes in the bone skeleton that have been formed by the time of diagnosis require long-term observation and treatment of the patient by a pediatric endocrinologist, pediatric orthopedist and rehabilitologist. Thus, based on the presented clinical observation, the conclusion is as follows: in order to minimize the risk of disability in children and adolescents with PHPT it is extremely important to establish the correct diagnosis as early as possible coupled with the timely etiotropic and pathogenetic treatment.

  • PRIMARY HYPOTHYROIDISM IN A HIGH-RISK NEUROBLASTOMA PATIENT AFTER 131I-MIBG THERAPY: A CLINICAL CASE REPORT AND LITERATURE REVIEW

    by D.T. Utalieva, Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology, S.B. Babakhanova, E.Yu. Ilyina, N.A. Andreeva, Yu.N. Likar, A.P. Shcherbakov, D.Yu. Kachanov, T.V. Shamanskaya

    In recent decades, there has been marked progress in understanding the biology of the most common extracranial solid tumor of childhood – neuroblastoma (NB), which led to a significant improvement in treatment outcomes due to stratification of patients into risk groups, intensification of treatment of patients with metastatic disease and the presence of unfavorable molecular genetic markers. Survivors who have received multimodal therapies, including chemotherapy, high-dose therapy and autologous peripheral stem-cell transplantation, 131I-metaiodobenzylguanidine (131I-MIBG) therapy, radiation therapy, and immunotherapy have a high risk of developing long-term side effects of treatment (LT SE). The study of the nature and frequency of LT SE after completion of therapy in patients with NB is important to ensure the quality of life and minimize severe health disorders. This article presents a literature review and description of a clinical case report of primary hypothyroidism in a high-risk patient with NB who received multicomponent treatment, including 131I-metaiodobenzylguanidine therapy due to the persistence of MIBG-positive foci after the induction chemotherapy.


  • Open Access

    Bilateral adrenal neuroblastoma: clinical presentation, diagnostic and therapeutic approaches, treatment results

    by N. A. Andreeva, D. Yu. Kachanov, E. Yu. Ilyina, A. P. Shcherbakov, G. V. Tereshchenko, Yu. N. Likar, A. E. Druy, V. Yu. Roshchin, M. Ya. Yagdarov, T. V. Shamanskaya, et al.

    Bilateral adrenal neuroblastoma (BANB) is a very rare entity. It is more common in young children and has certain clinical features. Patients with BANB have a more favorable prognosis than patients with unilateral adrenal neuroblastoma (NB). The article presents an analysis of 29 cases of BANB in children who underwent treatment at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. This study is supported by the Independent Ethics Committee and approved by the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The analysis was performed for the period from April 2012 to December 2018. Bilateral adrenal involvement was diagnosed on the basis of analysis/assessment of the results of all relevant imaging and instrumental tests. Additionally, we performed a retrospective analysis of the findings of computed tomography, magnetic resonance imagining, and scintigraphy with 123I-metaiodobenzylguanidine (123I-MIBG). In view of 123I-MIBG scintigraphy sensitivity threshold, and in order to confirm the diagnosis, imaging findings were reviewed by an experienced radiologist. The patients received therapy in accordance with the risk-adapted NB-2004 protocol. Here, we analyzed the details of clinical presentation of the disease, age at the time of diagnosis, time from the disease onset to diagnosis, the presence or absence of life-threatening symptoms (LTS) and adrenal insufficiency, the aspects of patient management (including special aspects of surgical treatment), and treatment results. The median age at the time of diagnosis was 1.9 months. The patients were divided into 3 groups: children with localized BANB; children with true stage 4 disease; children with stage 4S disease. Most patients had metastatic NB, whereby stage 4S cases prevailed (55%, n = 16). Given the low sensitivity of MIBG scintigraphy for the detection of small tumours (less than 2 cm), one should use a comprehensive approach to the assessment of the results of imaging and instrumental tests in patients with BANB in order to confirm bilateral involvement. At diagnosis, about half of the patients with BANB (48%) had clinical symptoms associated with the presence of a retroperitoneal tumour mass and massive hepatomegaly because of liver metastases. Thirty-four percent of patients developed LTS. One of the typical features of BANB was the frequent development of adrenal insufficiency (in 41% of cases) caused by bilateral adrenal involvement, and this should be taken into account when performing diagnostic investigations and providing treatment to patients. Since bilateral radical resection is associated with the inevitable development of adrenal insufficiency, surgical treatment should be determined on an individual basis. Bilateral adrenalectomy is not generally recommended and can be undertaken after an interdisciplinary discussion in case of unfavourable course of the disease (e.g. in case of recurrence). Even if patients with BANB develop certain complications or events (progression) their prognosis is still good. The three- and five-year event-free survival rates in patients with BANB were 86 ± 6.4%. The three- and five-year overall survival rates were 100%. The analysis of patients with BANB showed that they have a more favourable course of the disease, and this may serve as grounds for assigning such patients into a special group. In view of the degree of tumour extension, the specifics of staging, and frequent development of adrenal insufficiency, standard check-ups should be complemented by endocrine monitoring, and surgical approaches should be chosen on an individual basis.